Regenxbio (RGNX) Equity Average (2015 - 2025)

Regenxbio's Equity Average history runs 11 years deep, the most recent figure standing at $132.1 million for Q4 2025.

• In Q4 2025, Equity Average fell 52.91% year-over-year to $132.1 million; the TTM figure through Dec 2025 stood at $132.1 million (down 52.91% YoY), while the FY2025 annual figure was $181.2 million, down 36.58% from the prior year.
• Equity Average was $132.1 million for Q4 2025 at Regenxbio, down from $187.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $727.0 million in Q1 2022 to a low of $132.1 million in Q4 2025.
• Historically, Equity Average has averaged $421.2 million across 5 years, with a median of $410.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Equity Average soared 55.96% in 2022, then sank 52.91% in 2025.
• A 5-year view of Equity Average shows it stood at $612.9 million in 2021, then fell by 11.89% to $540.0 million in 2022, then plunged by 37.52% to $337.4 million in 2023, then retreated by 16.86% to $280.5 million in 2024, then tumbled by 52.91% to $132.1 million in 2025.
• The last three Equity Average figures came in at $132.1 million (Q4 2025), $187.6 million (Q3 2025), and $243.9 million (Q2 2025), per Business Quant data.